Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • Brazil
    • Canada
    • United States
    • Mexico
    • Colombia
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Romania
    • Hungary
    • Slovakia
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Investors
  3. Regulated Information

Regulated Information

  • Regulated Information
  • Shareholders Meeting

Period

recent search

Reset

Showing: 1 – 5 of 203 Regulated Information

13 June 2025

13 June 2025

Download IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2025

12 June 2025

12 June 2025

Download Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – May 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

02 June 2025

02 June 2025

Download Ipsen S.A. - Initiation of the share buy-back program
Ipsen S.A. – Initiation of the share buy-back program

12 May 2025

12 May 2025

Download Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – April 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital

30 April 2025

30 April 2025

Download Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
Ipsen S.A. – Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting

1 … 15 16 17 18 19 20 21 … 41

IPN price

€155.90

 €0.10 (0.06%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy
  • LinkedIn
  • Instagram
  • Facebook
  • Youtube

© Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

What information or content were you unable to find on the Ipsen website?